Non-Hodgkin Lymphoma Treatment Market by Treatment Type, Application, End-User

Description

List of Tables

[185 Pages Report] The Non-Hodgkin Lymphoma Treatment Market size was estimated at USD 8.20 billion in 2023 and expected to reach USD 8.84 billion in 2024, at a CAGR 7.91% to reach USD 13.98 billion by 2030.

Non-Hodgkin Lymphoma refers to a type of cancer that begins and develops in the lymph nodes and lymphatic tissue found in organs, including the stomach and intestines. Swollen lymph nodes in the neck, abdominal pain or swelling, chest pain, coughing, or trouble breathing are some common symptoms of the disease. Treatment options for non-Hodgkin lymphoma (NHL) include chemotherapy, radiation, plasmapheresis targeted therapy, and stem cell transplant. Newer treatment options for non-Hodgkin lymphoma are focused on making personalized medications, targeted drugs, and immunotherapy engineered to attack cancer cells specifically. Changing lifestyles and rising incidences of obesity have led to a surge in the number of patients suffering from cancers and tumors. Additionally, the launch of promising drugs and the number of drug approvals for lymphomas is rapidly increasing. However, the high cost of availing cancer treatment options reduces the accessibility of treatment options. Furthermore, stringent regulations for cancer treatment options have dissuaded research institutions from investing in cancer treatment research and have hampered the commercialization of novel drugs. The government's focus on increasing awareness about cancer and its treatment options is gaining traction and can aid in reducing the number of barriers posed by complex regulations. Biotechnology, and pharmaceutical institutions and companies have introduced targeted biological therapies and drug options for cancer, such as antibody-drug conjugate and proteasome inhibitors.

KEY MARKET STATISTICS
Base Year [2023]	USD 8.20 billion
Estimated Year [2024]	USD 8.84 billion
Forecast Year [2030]	USD 13.98 billion
CAGR (%)	7.91%

Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body

Chemotherapy prevents the division and growth of cancer cells, thereby preventing the progression of cancers. It is provided through a drip directly into the vein (intravenous chemotherapy), as tablets or a combination of both. Besides, some chemotherapy drugs can cause painful side effects, such as aching in the muscles and joints, headaches and stomach pains. Immunotherapy is another type of cancer treatment that uses the patient's body's immune system to destroy cancer cells and uses antibodies, monoclonal or bispecific antibodies, to target cancer cells. Radiation therapy uses rays of intense energy, often X-rays, to kill cancer cells. External radiation therapy is the most commonly used treatment strategy for NHL). Stem cell transplants are procedures that are used to replace cancerous, damaged stem cells with healthy ones. Targeted therapy refers to cancer treatment that utilizes chemical drugs to specifically identify and attack certain cancer cells. Targeted therapy can be used as a treatment option in itself or in combination with other treatments, such as traditional or standard chemotherapy or radiation therapy.

Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)

Diffuse large B cell lymphoma (DLBCL) refers to a type of non-Hodgkin lymphoma (NHL) that starts developing when the patient's body makes abnormal B lymphocytes and proliferates quickly. The treatment strategies used include chemotherapy in combination with drugs or treatment with plus monoclonal antibodies. Follicular lymphoma refers to a type of low-grade non-Hodgkin lymphoma (NHL) that is formed due to the clustering of white blood cells in the lymph glands or organs. Radiation, immunochemotherapy, and immunotherapy are commonly used treatment options. Mantle Cell lymphoma (MCL) is an aggressive, rare form of non-Hodgkin lymphoma (NHL) that affects the mantle zone of the lymph node. Often, chemotherapy drugs and immunotherapy are used to treat such cancers.

End-user: Increasing adoption of novel strategies for NHL treatment in hospitals

Hospitals are rapidly adopting immunotherapies and chemotherapies for the treatment of NHL. They are also investing in the development of novel therapies that don't require an overnight stay in hospitals. Cancer centers refer to institutions that develop and translate scientific knowledge generated from the latest research activities into promising laboratory treatments for cancer patients. Home care services allow a patient to acquire treatment and care from their own homes and is specifically advantageous for elderly patients and patients with special needs. Home care services involve a range of health, social, and rehabilitative services for the recovery of patients.

Regional Insights

Significant Americas countries, such as the USA and Canada, are associated with a higher awareness of the availability of treatment options and reimbursement plans for cancer treatment. The Americas market for NHL treatment is driven by the increasing number of cancer care centers and oncology specialists in the region. Additionally, Americas countries are characterized by the presence of major biotechnology and pharmaceutical companies and a large number of treatment solutions introduced for Non hodgkin lymphoma. Countries in Asia, including China, have expanded their focus on increasing the number of drug approvals for cancer treatment. Governments are rapidly investing their efforts to improve awareness of lymphomas and their symptoms. European nations have well-established academic and research institutions that are actively involved in research and development activities concerning non-Hodgkin lymphoma and other cancers. Additionally, the growing number of clinical trials and collaborations between biotechnology companies and governments has been a significant driving factor towards the introduction of novel treatment therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Non-Hodgkin Lymphoma Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Non-Hodgkin Lymphoma Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Non-Hodgkin Lymphoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Aurobindo Pharma, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Drugs Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Janssen Global Services, LLC, Kyowa Kirin Co., Ltd., Lupin Ltd., Merck KGaA, Nordic Nanovector ASA by Thor Medical, Novartis AG, Pharmacyclics, LLC, Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Non-Hodgkin Lymphoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment Type
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Stem Cell Transplantation
- Targeted Therapy

Application
- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma

End-User
- Cancer Centers
- Home Care
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Non-Hodgkin Lymphoma Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Non-Hodgkin Lymphoma Treatment Market?

3. What are the technology trends and regulatory frameworks in the Non-Hodgkin Lymphoma Treatment Market?

4. What is the market share of the leading vendors in the Non-Hodgkin Lymphoma Treatment Market?

5. Which modes and strategic moves are suitable for entering the Non-Hodgkin Lymphoma Treatment Market?

Product Code: MRR-036C5CF3B518

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of non-Hodgkin lymphoma disease
  - 5.1.1.2. The launch of promising drugs and drug approval for lymphomas
  - 5.1.1.3. Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
- 5.1.2. Restraints
  - 5.1.2.1. High cost of the treatment and certain side effects
- 5.1.3. Opportunities
  - 5.1.3.1. Increase in research and development of therapeutic drugs against the disease
  - 5.1.3.2. Rising investments from government and non-profit organizations
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulations for cancer treatment options
5.2. Market Segmentation Analysis
- 5.2.1. Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body
- 5.2.2. Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)
- 5.2.3. End-user: Increasing adoption of novel strategies for NHL treatment in hospitals
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type

6.1. Introduction
6.2. Chemotherapy
6.3. Immunotherapy
6.4. Radiation Therapy
6.5. Stem Cell Transplantation
6.6. Targeted Therapy

7. Non-Hodgkin Lymphoma Treatment Market, by Application

7.1. Introduction
7.2. Diffuse Large B-cell Lymphoma
7.3. Follicular Lymphoma
7.4. Mantle Cell Lymphoma

8. Non-Hodgkin Lymphoma Treatment Market, by End-User

8.1. Introduction
8.2. Cancer Centers
8.3. Home Care
8.4. Hospitals

9. Americas Non-Hodgkin Lymphoma Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- 12.3.2. Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
- 12.3.3. Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio